2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
J Herrmann, D Lenihan, S Armenian… - European heart …, 2022 - academic.oup.com
Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …
targeted cancer therapies. Both general measures and specific pharmacologic …
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
N Dempsey, A Rosenthal, N Dabas… - Breast Cancer Research …, 2021 - Springer
Purpose Despite great success as a targeted breast cancer therapy, trastuzumab use may
be complicated by heart failure and loss of left ventricular contractile function. This review …
be complicated by heart failure and loss of left ventricular contractile function. This review …
Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review
LA Baldassarre, S Ganatra, J Lopez-Mattei… - Journal of the American …, 2022 - jacc.org
The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review
G Georgiopoulos, N Makris, A Laina, F Theodorakakou… - Cardio Oncology, 2023 - jacc.org
Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …
Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial
T Negishi, P Thavendiranathan, M Penicka… - Cardiovascular …, 2023 - jacc.org
Background Global longitudinal strain (GLS) can predict cancer therapeutics–related
cardiac dysfunction and guide initiation of cardioprotection (CPT). Objectives In this study …
cardiac dysfunction and guide initiation of cardioprotection (CPT). Objectives In this study …